Sector News

Boston Scientific acquires EMcision Ltd

March 6, 2018
Life sciences

EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, today announced that it and its subsidiaries have been acquired by Boston Scientific, the world’s premier endoscopic devices company.

Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the HabibTM 4X, the HabibTM EndoHPB and the HabibTM EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.

EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.

“Recently, two randomised clinical trials showed independently a statistically significant survival advantage for patients treated with the HabibTM EndoHPB,” said Prof. Nagy Habib, EMcision’s Chairman and founder. “This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer.”

EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centres such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General and Stanford.

“By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients,” said Cherif Habib, EMcision’s outgoing CEO.

Boston Scientific, headquartered in Marlborough, Massachusetts, was founded in 1979 and employs over 27,000 people. Their products, across six business divisions, treat over 24 million patients every year.

Source: EMcision

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach